Ariawan Armoko/iStock via Getty Images Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a good long-term biotech to own in my opinion. That's because it has already been able to receive regulatory approvals for several of its drugs in its pipeline. Matter of fact, the drugs being sold by the company are Crysvita and Dojolvi. In Q1 of 2024, it generated $109 million in total revenue, which was an 8% growth year-over-year. As such, if sales continue like this, it will continue to build shareholder value. I ...